11 March 2021

The Coalition for Epidemic Preparedness Innovations (CEPI) and biopharmaceutical company VBI Vaccines have entered into a partnership to advance and develop the latter’s enveloped virus like particle (eVLP) vaccine candidates against Covid-19 variants. CEPI will offer up to $33m to support the development of VBI-2905, a monovalent eVLP candidate, in a Phase I clinical trial.

Softbox announced that it will be supporting Pfizer in the global distribution of Covid-19 vaccines. The vaccines will be transported in a high-performance temperature controlled parcel shipper developed precisely for ultra-low temperature products.

Moderna announced that it has successfully dosed the first participants with its modified Covid-19 vaccines in an amended ongoing Phase II clinical study. mRNA-1273.351 is being evaluated as a booster vaccine to assess a broader immune response to emerging variants, while mRNA-1273.211 is a multivalent candidate which combines mRNA-1273, Moderna’s authorised vaccine against ancestral strains.